Q-omics provides the consensus-scored ZNF761 profile across patient tissues and cancer cell-line models. ZNF761 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF761 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, ZNF761 RNA expression shows 20,700 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, BLCA, and UVM as cancer lineages where ZNF761 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF761 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF761 survival associations across molecular data types. ZNF761 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF761 RNA expression–survival associations across cancer types. High ZNF761 expression shows unfavorable associations in MESO, LGG, LUSC, CESC, ACC and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF761 RNA expression.
This table summarizes ZNF761 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF761. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF761 shows lower tumor expression in THCA and higher tumor expression in BLCA, COAD, STAD, HNSC and LIHC. The BLCA box plot shows higher ZNF761 RNA expression in tumor versus normal tissue (log2 FC = +1.032, t-test p < 0.001).
This table shows molecular features associated with ZNF761 in patient tissues and cancer cell lines. In patient samples, ZNF761 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF761 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma.
